Madrigal Pharmaceuticals Cash Flow Statement
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
471.75-5.16 (-1.08%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Madrigal Pharmaceuticals free cash flow
In fiscal 2025, Madrigal Pharmaceuticals generated -$189.6 million of operating cash flow and spent $467,000 on capital expenditures. That left free cash flow of -$190.0 million, a free-cash-flow margin of -19.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Madrigal Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -288.28M | -465.89M | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.51M | 1.10M | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156 |
| Stock-Based Compensation | 98.13M | 79.88M | 49.73M | 31.63M | 26.87M | 20.73M | 22.76M | 13.49M | 3.25M | 7.93M |
| Change in Working Capital | -14.47M | -48.25M | 2.17M | 37.61M | 29.86M | 21.56M | 15.81M | -2.61M | 5.51M | -1.11M |
| Operating Cash Flow | -189.55M | -455.57M | -324.23M | -224.86M | -183.92M | -157.56M | -41.62M | -25.51M | -22.32M | -17.61M |
| Capital Expenditures | -467.00K | -1.46M | -1.48M | -217.00K | -209.00K | -334.00K | -172.00K | -22.00K | -125.00K | -3.00K |
| Investing Cash Flow | 32.32M | -274.39M | -502.52M | 206.69M | -5.05M | 159.78M | 30.71M | -380.08M | -22.01M | 21.99M |
| Financing Cash Flow | 255.98M | 735.06M | 595.12M | 313.45M | 171.24M | 5.09M | 235.00K | 314.33M | 173.81M | 14.45M |
| Net Change in Cash | 98.76M | 5.10M | -231.63M | 295.28M | -17.73M | 7.31M | -10.68M | -91.25M | 129.48M | 18.84M |
| Free Cash Flow | -190.02M | -457.03M | -325.71M | -225.07M | -184.13M | -157.90M | -41.80M | -25.53M | -22.44M | -17.61M |
This table shows 10 annual periods of Madrigal Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MDGL's reporting calendar. What is a cash flow statement?